Telomir Pharmaceuticals, Inc.

8-K · form8-k.htm

0001971532

 2026-06-03
 2026-06-03

 iso4217:USD

 xbrli:shares

 iso4217:USD

 xbrli:shares

  

  

  

 UNITED
STATES

 SECURITIES
AND EXCHANGE COMMISSION

 WASHINGTON,
D.C. 20549

  

 FORM
 8-K

  

 CURRENT
REPORT

  

 Pursuant
to Section 13 or 15(d) of the

 Securities
Exchange Act of 1934

  

 Date
of Report (Date of earliest event reported): June 3, 2026

  

 TELOMIR
PHARMACEUTICALS, INC.

 (Exact
Name of Registrant as Specified in its Charter)

  

 Florida
  
 001-41952
  
 87-2606031

 (State
 or Other Jurisdiction
  
 (Commission
  
 (IRS
 Employer

 of
 Incorporation)
  
 File
 Number)
  
 Identification
 No.)

  

 100
SE 2nd St , Suite 2000 , #1009

 Miami ,
 Florida 33131

 (Address
of Principal Executive Offices)

  

 Registrant’s
telephone number, including area code: (786) 396-6723

  

 Not
Applicable

 (Former
Name or Former Address, if Changed Since Last Report)

  

 Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:

  

  
 ☐
 Written
 communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

  
  
  

  
 ☐
 Soliciting
 material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

  
  
  

  
 ☐
 Pre-commencement
 communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  
  
  

  
 ☐
 Pre-commencement
 communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  

 Securities
registered pursuant to Section 12(b) of the Act:

  

 Title
 of each class
  
 Trading
 Symbol
  
 Name
 of each exchange on which registered

 Common
 Stock, no par value
  
 TELO
  
 The
 Nasdaq Stock Market LLC

  

 Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

  

 Emerging
growth company ☒

  

 If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

  

  

  

  

  

  

 Item
 5.02
 Departure
 of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

  

 Appointment
of Andriy Mushak as the Fractional Chief Financial Officer

  

 Effective
June 6, 2026, Alan Weichselbaum will be no longer serving as the Chief Financial Officer of Telomir Pharmaceuticals, Inc. (the “Company”).
Mr. Weichselbaum’s departure was not the result of any disagreement with the Company on any matter relating to the Company’s
operations, policies, or practices. On June 3, 2026, the board of directors of the Company appointed Andriy Mushak to serve as the Company’s
fractional Chief Financial Officer, effective as of June 6, 2026 (the “Effective Date”).

  

 Mr.
Mushak, CPA, 43, is an accomplished Certified Public Accountant licensed in the Commonwealth of Massachusetts with over 20 years of experience
in SEC reporting, accounting compliance, and financial statement audits. Mr. Mushak currently serves as a Partner at LMAM Consulting
Group, LLC (“LMAM”), a professional services firm with offices in Dallas, Texas and Boston, Massachusetts, specializing in
SEC financial reporting, technical accounting, and M&A transaction support. At LMAM, Mr. Mushak leads SEC reporting engagements,
financial statement preparation, and advisory services for both publicly traded and privately held companies across diverse industries,
including technology, life sciences, media, medical supplies, finance, and manufacturing. Prior to co-founding LMAM in 2025, Mr. Mushak
served in the Audit practice at Baker Tilly US, LLP (Boston) for over a decade, most recently as a Senior Manager, where he led financial
statement audits and provided assurance and advisory services for publicly traded and privately held clients. Mr. Mushak earned a Master
of Science in Accounting and Auditing and a Bachelor of Arts in Economics from Buchach Institute of Management and Audit. Mr. Mushak
is a Certified Public Accountant licensed by the Massachusetts Board of Public Accountancy.

  

 Mr.
Mushak has been, and will remain, employed by LMAM and will be providing his services pursuant to the Consulting Agreement between the
Company and LMAM. The material terms of the engagement are that the Company will pay Mr. Mushak $6,000 per month for the services rendered
by Mr. Mushak.

  

 There
are no family relationships, as defined in Item 401 of Regulation S-K, between Mr. Mushak and any of the Company’s executive officers
or directors or persons nominated or chosen to become a director or executive officer.

  

 Mr.
Mushak has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation
S-K.

  

 Item
9.01 Financial Statements and Exhibits

  

 (d)
Exhibits

  

 10.1
  
 Consulting Agreement between Telomir Pharmaceuticals, Inc. LMAM Consulting Group, LLC

 104
  
 Cover
 Page Interactive Data File (embedded within the Inline XBRL document)

  

  

  

  

 SIGNATURES

  

 Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

  

  
 TELOMIR
 PHARMACEUTICALS, INC.

  
  
  

 Dated:
 June 8, 2026
 By:
 /s/
 Erez Aminov           

  
 Name:
 Erez
 Aminov

  
 Title:
 Chief
 Executive Officer